Sugi Predict

Sugi Predict / Compounds / SCHEMBL4356694

SCHEMBL4356694

SCHEMBL4356694

COc1ccccc1-c1nn(COCC[Si](C)(C)C)c2ncc(-c3cccc(C(C)(O)C(=O)O)c3)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 4/20 0.35
▸ PAX8 Q06710 1/20 0.34
▸ MERTK Q12866 2/20 0.34
▸ PTPN11 Q06124 1/20 0.34
▸ PTGES2 Q9H7Z7 1/20 0.33
▸ SLC6A9 P48067 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ PTPN5 P54829 1/20 0.33
▸ EGLN1 Q9GZT9 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ IGF1R P08069 1/20 0.32
▸ SRC P12931 1/20 0.32
▸ FLT4 P35916 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ EPHB4 P54760 1/20 0.32
▸ TEK Q02763 1/20 0.32
▸ AXL P30530 1/20 0.32
▸ TYRO3 Q06418 1/20 0.32
▸ MAP4K1 Q92918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4362059 0.92 MAP4K1 (0.35) DGAT1MERTKPTPN11SLC6A9PTPN5
SCHEMBL4359217 0.85 FYN (0.37) PTPN11EGLN1AXLMAP4K1
SCHEMBL3488599 0.85 TP53 (0.39) PTPN11SLC6A9EGLN1
SCHEMBL5064598 0.84 FABP3 (0.38) DGAT1MERTKSLC6A9EGLN1EGFR
SCHEMBL4364267 0.84 AKR1C3 (0.38) —
SCHEMBL4361942 0.83 CTSA (0.36) SLC6A9MAP4K1
SCHEMBL4357157 0.83 SLC6A9 (0.35) DGAT1SLC6A9EGLN1MAP4K1
SCHEMBL3377327 0.83 AXL (0.36) DGAT1PAX8MERTKEGFRIGF1R
SCHEMBL3489403 0.83 CHEK1 (0.38) MERTKEGFRIGF1RSRCFLT4
SCHEMBL3489384 0.82 MAP4K1 (0.36) SLC6A9MAP4K4MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
EP-2078020-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-07-15 — — EP disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
WO-2008124848-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, MAP3K19, MAP4K2 DGAT1 2794/4885PAX8 4476/4885MERTK 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.